Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19.
作者信息
Shafat Tali, Grupel Daniel, Porges Tzvika, Levi Itai, Yagel Yael, Nesher Lior
机构信息
Infectious Diseases Institute, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Clinical Research Center, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
出版信息
Br J Haematol. 2022 Sep;198(5):826-829. doi: 10.1111/bjh.18315. Epub 2022 Jun 19.
Abstract
摘要
相似文献
1
Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19.对于被诊断感染奥密克戎变异株新冠病毒的血液学患者，使用奥妥珠单抗治疗会导致更差的预后。
Br J Haematol. 2022 Sep;198(5):826-829. doi: 10.1111/bjh.18315. Epub 2022 Jun 19.
2
Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study.奥滨尤妥珠单抗治疗与利妥昔单抗治疗的 COVID-19 患者结局比较：一项回顾性队列研究。
Virol J. 2024 Sep 9;21(1):212. doi: 10.1186/s12985-024-02484-x.
3
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.一项国际多中心研究比较了奥密克戎变异株在接受奥滨尤妥珠单抗与利妥昔单抗治疗的血液系统恶性肿瘤患者中的结局。
Cancer Med. 2024 Feb;13(3):e6997. doi: 10.1002/cam4.6997.
4
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.针对严重急性呼吸综合征冠状病毒 2 株 delta 和 omicron 变异株的单克隆抗体的临床疗效和体外中和能力。
J Med Virol. 2022 Oct;94(10):5038-5043. doi: 10.1002/jmv.27916. Epub 2022 Jun 11.
5
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.成功使用 casirivimab/imdevimab 抗刺突单克隆抗体增强了一名接受抗 CD20 治疗的难治性 COVID-19 女性的中和抗体。
J Infect Chemother. 2022 Jul;28(7):991-994. doi: 10.1016/j.jiac.2022.03.002. Epub 2022 Mar 23.
6
[Sotrovimab in controlling SARS-CoV-2 infection].[索托维单抗在控制新型冠状病毒2感染中的作用]
Pol Merkur Lekarski. 2022 Feb 22;50(295):48-50.
7
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab.接受索托维单抗治疗患者中新冠病毒奥密克戎变体的耐药突变
Clin Microbiol Infect. 2022 Sep;28(9):1297-1299. doi: 10.1016/j.cmi.2022.05.002. Epub 2022 May 17.
8
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.针对 SARS-CoV-2 奥密克戎变异株关切性的单克隆抗体临床疗效的探索性数据。
Elife. 2022 Nov 22;11:e79639. doi: 10.7554/eLife.79639.
9
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.病例报告：缺乏疫苗应答的多发性硬化症患者中针对 SARS-CoV-2 感染的变异特异性预先暴露预防。
Front Immunol. 2022 Jul 25;13:897748. doi: 10.3389/fimmu.2022.897748. eCollection 2022.
10
Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients.索托维单抗促使免疫功能低下患者体内的新冠病毒奥密克戎变种发生进化。
Lancet Microbe. 2022 Aug;3(8):e559. doi: 10.1016/S2666-5247(22)00120-3. Epub 2022 May 27.
引用本文的文献
1
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study.替沙格韦单抗-西加韦单抗预防接受抗CD20单克隆抗体治疗的血液病患者发生重症新型冠状病毒肺炎：一项国际多中心研究
Infect Dis Ther. 2025 Jan;14(1):167-180. doi: 10.1007/s40121-024-01089-9. Epub 2024 Dec 9.
2
Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic.奥妥珠单抗治疗膜性肾病：COVID-19大流行期间的有效性和安全性问题
Clin Kidney J. 2024 Oct 4;17(11):sfae299. doi: 10.1093/ckj/sfae299. eCollection 2024 Nov.
3
In the SARS-CoV-2 era, do we need to be afraid of obinutuzumab?在新型冠状病毒肺炎（SARS-CoV-2）流行时代，我们需要害怕奥滨尤妥珠单抗吗？
Br J Haematol. 2024 Dec;205(6):2113-2115. doi: 10.1111/bjh.19786. Epub 2024 Sep 27.
4
Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study.奥滨尤妥珠单抗治疗与利妥昔单抗治疗的 COVID-19 患者结局比较：一项回顾性队列研究。
Virol J. 2024 Sep 9;21(1):212. doi: 10.1186/s12985-024-02484-x.
5
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.对于新诊断的晚期滤泡性淋巴瘤的接种疫苗患者，暴露于奥妥珠单抗并不影响其感染SARS-CoV-2的结果。
Br J Haematol. 2024 Dec;205(6):2219-2227. doi: 10.1111/bjh.19661. Epub 2024 Jul 22.
6
Caution to psychiatry ward: COVID-19 pneumonia can manifest weeks or months after testing positive with a PCR test in individuals on preexisting immune-suppressing medication.精神科病房注意：对于正在服用免疫抑制药物的个体，新冠病毒肺炎可能在PCR检测呈阳性数周或数月后才表现出来。
PCN Rep. 2023 Aug 27;2(3):e135. doi: 10.1002/pcn5.135. eCollection 2023 Sep.
7
Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin's Lymphoma: A Single-Center Cohort Study.COVID-19 mRNA 疫苗加强针的初步疗效及随后在 B 细胞非霍奇金淋巴瘤患者中奥密克戎变异株突破性感染的研究：一项单中心队列研究。
Viruses. 2024 Feb 21;16(3):328. doi: 10.3390/v16030328.
8
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.一项国际多中心研究比较了奥密克戎变异株在接受奥滨尤妥珠单抗与利妥昔单抗治疗的血液系统恶性肿瘤患者中的结局。
Cancer Med. 2024 Feb;13(3):e6997. doi: 10.1002/cam4.6997.
9
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era-A Study of KroHem, the Croatian Group for Hematologic Diseases.前奥密克戎时代淋巴瘤患者COVID-19不良结局的治疗相关风险因素——克罗地亚血液疾病小组KroHem的一项研究
Biomedicines. 2024 Jan 31;12(2):331. doi: 10.3390/biomedicines12020331.
10
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.奥密克戎相关的 COVID-19 血液病患者防治措施及血液学治疗方案调整策略。
Front Cell Infect Microbiol. 2023 Oct 19;13:1207225. doi: 10.3389/fcimb.2023.1207225. eCollection 2023.
本文引用的文献
1
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).COVID-19 感染成年血液病患者：欧洲血液学协会调查（EPICOVIDEHA）。
J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0.
2
Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies.抗 CD20 单克隆抗体治疗患者严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的发生率、临床表现、复发和结局。
Clin Infect Dis. 2022 May 30;74(10):1786-1794. doi: 10.1093/cid/ciab700.
3
SARS-CoV-2 universal screening upon adult hospital admission in Southern Israel.以色列南部成人住院时进行的 SARS-CoV-2 普遍筛查。
J Hosp Infect. 2021 Aug;114:167-170. doi: 10.1016/j.jhin.2021.04.026. Epub 2021 Apr 30.
4
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease.利妥昔单抗的使用与患有系统性风湿疾病的COVID-19患者不良临床结局的风险
Rheumatol Int. 2020 Dec;40(12):2117-2118. doi: 10.1007/s00296-020-04715-0. Epub 2020 Oct 12.
5
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.一线采用苯达莫司汀-利妥昔单抗治疗滤泡淋巴瘤后维持利妥昔单抗或观察。
Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21.
6
A tale of two antibodies: obinutuzumab versus rituximab.两抗体的故事：奥滨尤妥珠单抗对比利妥昔单抗。
Br J Haematol. 2018 Jul;182(1):29-45. doi: 10.1111/bjh.15232. Epub 2018 May 9.
7
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.奥滨尤妥珠单抗用于滤泡性淋巴瘤的一线治疗。
N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.
8
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.利妥昔单抗维持治疗对利妥昔单抗联合化疗后高肿瘤负荷滤泡性淋巴瘤患者的影响（PRIMA）：一项 3 期随机对照试验。
Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
Zotero 插件